Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | GPR3 | P46089 | 1/20 | 0.46 |
| ▸ | EGFR | P00533 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | STAT3 | P40763 | 1/20 | 0.42 |
| ▸ | HTR3A | P46098 | 1/20 | 0.42 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.42 |
| ▸ | AR | P10275 | 1/20 | 0.39 |
| ▸ | MGAM | O43451 | 2/20 | 0.38 |
| ▸ | BCHE | P06276 | 1/20 | 0.38 |
| ▸ | NCF1 | P14598 | 1/20 | 0.38 |
| ▸ | NOS2 | P35228 | 1/20 | 0.38 |
| ▸ | BACE1 | P56817 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31235102 | 1.00 | KDM4E (0.46) | KDM4EGPR3EGFRALDH1A1HPGD | |
| SCHEMBL28762595 | 0.98 | KDM4E (0.45) | KDM4EGPR3EGFRALDH1A1HPGD | |
| Hydrochloric Acid SCHEMBL27927852 | 0.98 | KDM4E (0.45) | KDM4EGPR3EGFRALDH1A1HPGD | |
| Hypophosphorous Acid SCHEMBL1654733 | 0.90 | KDM4E (0.39) | KDM4EGPR3EGFRALDH1A1HPGD | |
| Phosphonic Acid SCHEMBL4070174 | 0.90 | KDM4E (0.39) | KDM4EGPR3EGFRALDH1A1HPGD | |
| Trifluoroacetic Acid SCHEMBL6614032 | 0.84 | PAX8 (0.44) | KDM4EALDH1A1HPGDMAPTMGAM | |
| SCHEMBL6830494 | 0.78 | MAPT (0.36) | KDM4EALDH1A1HPGDMAPTCYP1A2 | |
| SCHEMBL30198446 | 0.75 | CYP1A2 (0.60) | KDM4EGPR3EGFRALDH1A1HPGD | |
| SCHEMBL1672650 | 0.75 | CYP1A2 (0.60) | KDM4EGPR3EGFRALDH1A1HPGD | |
| SCHEMBL30527184 | 0.75 | CYP1A2 (0.60) | KDM4EGPR3EGFRALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 375 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108117649-B | Organic porous material based on butterfly tricyclic quinazoline unit and synthetic method thereof | 中国科学院大连化学物理研究所 | 2020-05-19 | — | — | CN | claimed |
| US-20200101057-A1 | COMBINATION THERAPY AGAINST CHEMORESISTANCE IN LEUKEMIA | THE GENERAL HOSPITAL CORPORATION | 2020-04-02 | — | — | US | claimed |
| CN-110218193-A | 3- hydroxyquinazoline -2,4 (1H, 3H)-diketone derivative and the preparation method and application thereof | 山东大学 | 2019-09-10 | — | — | CN | claimed |
| WO-2018183559-A1 | COMBINATION THERAPY AGAINST CHEMORESISTANCE IN LEUKEMIA | THE GENERAL HOSPITAL CORPORATION (US) | 2018-10-04 | — | — | WO | claimed |
| WO-2016154694-A1 | N-ACYLHYDRAZONE COMPOUNDS INHIBITING HISTONE DESACETYLASE ENZYMES, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME, AND METHOD FOR PRODUCING SAME | UNIVERSIDADE FEDERAL DO RIO DE JANEIRO-UFRJ (BR) | 2016-10-06 | — | — | WO | claimed |
| CN-102850397-B | Multi-target antitumor compounds and preparation method and application thereof | UNIV BEIJING | 2015-02-18 | — | — | CN | claimed |
| CN-103910688-A | 2-propyl-4-chloroquinazoline derivative, its preparation method thereof and its application thereof | CHUNLIN CHEN | 2014-07-09 | — | — | CN | claimed |
| EP-0407237-B1 | Indolino-spiro-oxazine photochromic compounds, process for their preparation and photochromic compositions and materials containing them | ESSILOR INT (FR) | 1995-11-29 | — | — | EP | claimed |
| EP-0387119-B1 | Process for the condensation of at least one epoxide with at least one cyclic anhydride in the presence of a catalyst based on at least one nitrogen containing titanium complex | INST FRANCAIS DU PETROLE (FR) | 1993-11-18 | — | — | EP | claimed |
| US-5030711-A | Process for condensing at least one epoxide on at least one cyclic anhydride in the presence of a catalyst consisting of at least one titanium nitrogenous complex | INSTITUT FRANCAIS DU PETROLE (FR) | 1991-07-09 | — | — | US | claimed |
| US-4997910-A | Polyesters | INSTITUT FRANCAIS DU PETROLE (FR) | 1991-03-05 | — | — | US | claimed |
| EP-0407237-A2 | Indolino-spiro-oxazine photochromic compounds, process for their preparation and photochromic compositions and materials containing them | ESSILOR INTERNATIONAL (Compagnie Générale d'Optique) (FR) | 1991-01-09 | — | — | EP | claimed |
| EP-0031237-B1 | QUINAZOLINE DERIVATIVES, PROCESSES FOR THEIR PREPARATION, COMPOSITIONS CONTAINING THEM AND THEIR USE AS ANTI-CANCER AGENTS | NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) | 1984-10-17 | — | — | EP | claimed |
| JP-53044597-A | — | — | None | — | — | JP | disclosed |
| EP-4676600-A1 | PROTEIN KINASE INHIBITORS AND USES THEREOF | Deliver Therapeutics, Inc. (US) | 2026-01-14 | — | — | EP | disclosed |
| US-20250289830-A1 | KRAS INHIBITORS | ELI LILLY AND COMPANY | 2025-09-18 | — | — | US | disclosed |
| US-4141895-A | Hydroxyquinazolines and their use as intermediates for pharmaceutical agents | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1979-02-27 | — | — | US | disclosed |
| US-4141895-A | Hydroxyquinazolines and their use as intermediates for pharmaceutical agents | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1979-02-27 | — | — | US | disclosed |
| JP-S5344597-A | CONDENSED QUINAZOLINOL DERIVATIVE | DAI ICHI SEIYAKU CO LTD | 1978-04-21 | — | — | JP | disclosed |
| US-4038240-A | PROCESS FOR DYEING POLYURETHANE RESINS | BAYER AKTIENGESELLSCHAFT (DT) | 1977-07-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250289830-A1 | KRAS INHIBITORS | KRAS, NRAS, HRAS | KDM4E 2640/4885GPR3 745/4885EGFR 26/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.